Search hospitals

>

New York

>

Brooklyn

New York Methodist Hospital

Claim this profile

Brooklyn, New York 11215

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Prostate Cancer

Conducts research for Heart Failure

Conducts research for Brain Tumor

218 reported clinical trials

14 medical researchers

Photo of New York Methodist Hospital in BrooklynPhoto of New York Methodist Hospital in BrooklynPhoto of New York Methodist Hospital in Brooklyn

Summary

New York Methodist Hospital is a medical facility located in Brooklyn, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Heart Failure, Brain Tumor and other specialties. New York Methodist Hospital is involved with conducting 218 clinical trials across 354 conditions. There are 14 research doctors associated with this hospital, such as Hani Ashamalla, M.D., Scott Tagawa, MD, Uqba Khan, and Evelyn Taiwo, M.D..

Area of expertise

1

Breast Cancer

Global Leader

New York Methodist Hospital has run 22 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
HER2 positive
2

Lung Cancer

Global Leader

New York Methodist Hospital has run 22 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage I
Stage IV

Top PIs

Clinical Trials running at New York Methodist Hospital

Breast Cancer

Bladder Cancer

Bladder Carcinoma

Heart Failure

Prostate Cancer

Kidney Cancer

Esophageal cancer

Brain Tumor

Lung Cancer

Breast cancer

Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

Recruiting

2 awards

Phase 3

19 criteria

Image of trial facility.

Low Dose Tamoxifen

for Breast Cancer

This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy to treat postmenopausal women with hormone-dependent breast cancer. Giving low dose tamoxifen may be more effective compared to usual hormone therapy in treating post-menopausal women with hormone-positive, HER2 negative early stage breast cancer.

Recruiting

2 awards

Phase 3

8 criteria

Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at New York Methodist Hospital?